Amgen Inc.
High titer recombinant AAV vector production in adherent and suspension cells
Last updated:
Abstract:
The present invention is directed to an in vitro method of producing a recombinant AAV virion in a mammalian host cell that comprises a functional adenoviral E1A gene and rAAV virions made by the method. Host cells are transfected with varying ratios of plasmids comprising the E1A gene and virions.
Status:
Grant
Type:
Utility
Filling date:
28 Aug 2014
Issue date:
3 Aug 2021